A new, one-time gene therapy has demonstrated unprecedented success in treating Huntington's disease, a fatal inherited neurodegenerative disorder. The treatment, developed by uniQure and trialed at University College London, involves a complex 12-18 hour neurosurgery to infuse a safe virus deep into the brain. This virus delivers a genetic sequence that instructs brain cells to produce microRNA, which in turn silences the messenger RNA responsible for creating the toxic mutant huntingtin protein. In a clinical trial of 29 patients, the therapy resulted in an average 75% slowing of clinical progression over three years and reduced neurofilament levels, a key biomarker for neuron death. The company plans to seek regulatory approval in the US in 2026, offering significant hope for what has been an untreatable disease.
Breakthrough Gene Therapy Offers Hope for Huntington's Disease
A Major Breakthrough: For the first time, a treatment has successfully slowed the progression of Huntington's disease, a devastating and fatal inherited brain disorder. Researchers described the results as "spectacular."
Impressive Clinical Results: In a clinical trial, the gene therapy slowed the disease's progression by an average of 75% over three years. This means a decline that would normally take one year would instead take four, potentially giving patients decades of good quality life.
The Science Behind the Treatment: The therapy is a one-time treatment that works by "gene silencing."
During a 12-18 hour neurosurgery, a safe virus carrying a new piece of DNA is infused into key brain regions.
This DNA instructs brain cells to create a molecule (microRNA) that intercepts and disables the instructions for building the toxic protein that causes Huntington's.
This permanently reduces the levels of the harmful protein, protecting brain cells from dying.
Biological Proof of Success: The treatment was proven to be saving brain cells. Levels of neurofilaments (a chemical marker of brain cell death) were lower in patients three years after surgery than they were at the start of the trial, reversing the expected increase.
Hope for Families: The breakthrough offers profound hope to families affected by the disease. The article highlights the story of Jack May-Davis, who carries the faulty gene that killed his father and now has a chance at a much longer, healthier life.
Future Steps and Challenges:
The company, uniQure, plans to apply for a license in the US in the first quarter of 2026.
The treatment is highly complex and is expected to be very expensive, which may limit initial availability.
A Move Towards Prevention: The success has paved the way for future trials aimed at preventing the disease entirely in individuals who have the gene but have not yet developed symptoms.
Error: value error Invalid operation: The response.text quick accessor requires the response to contain a valid Part, but none were returned. The candidate's finish_reason is 1.